Monoclonal antibody applications in travel medicine
Abstract For decades, immunoglobulin preparations have been used to prevent or treat infectious diseases. Since only a few years, monoclonal antibody applications (mAbs) are taking flight and are increasingly dominating this field. In 2014, only two mAbs were registered; end of October 2023, more th...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2024-01-01
|
| Series: | Tropical Diseases, Travel Medicine and Vaccines |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s40794-023-00212-x |
| _version_ | 1797350135391322112 |
|---|---|
| author | Hanna K. de Jong Martin P. Grobusch |
| author_facet | Hanna K. de Jong Martin P. Grobusch |
| author_sort | Hanna K. de Jong |
| collection | DOAJ |
| description | Abstract For decades, immunoglobulin preparations have been used to prevent or treat infectious diseases. Since only a few years, monoclonal antibody applications (mAbs) are taking flight and are increasingly dominating this field. In 2014, only two mAbs were registered; end of October 2023, more than ten mAbs are registered or have been granted emergency use authorization, and many more are in (pre)clinical phases. Especially the COVID-19 pandemic has generated this surge in licensed monoclonal antibodies, although multiple phase 1 studies were already underway in 2019 for other infectious diseases such as malaria and yellow fever. Monoclonal antibodies could function as prophylaxis (i.e., for the prevention of malaria), or could be used to treat (tropical) infections (i.e., rabies, dengue fever, yellow fever). This review focuses on the discussion of the prospects of, and obstacles for, using mAbs in the prevention and treatment of (tropical) infectious diseases seen in the returning traveler; and provides an update on the mAbs currently being developed for infectious diseases, which could potentially be of interest for travelers. |
| first_indexed | 2024-03-08T12:40:24Z |
| format | Article |
| id | doaj.art-71a6eef9903543719662831106bfdeb1 |
| institution | Directory Open Access Journal |
| issn | 2055-0936 |
| language | English |
| last_indexed | 2024-03-08T12:40:24Z |
| publishDate | 2024-01-01 |
| publisher | BMC |
| record_format | Article |
| series | Tropical Diseases, Travel Medicine and Vaccines |
| spelling | doaj.art-71a6eef9903543719662831106bfdeb12024-01-21T12:11:04ZengBMCTropical Diseases, Travel Medicine and Vaccines2055-09362024-01-0110111810.1186/s40794-023-00212-xMonoclonal antibody applications in travel medicineHanna K. de Jong0Martin P. Grobusch1Centre of Tropical Medicine and Travel Medicine, Department of Infectious Diseases, Amsterdam University Medical Centers, Location AMC, Amsterdam Infection and Immunity, Amsterdam Public Health, University of AmsterdamCentre of Tropical Medicine and Travel Medicine, Department of Infectious Diseases, Amsterdam University Medical Centers, Location AMC, Amsterdam Infection and Immunity, Amsterdam Public Health, University of AmsterdamAbstract For decades, immunoglobulin preparations have been used to prevent or treat infectious diseases. Since only a few years, monoclonal antibody applications (mAbs) are taking flight and are increasingly dominating this field. In 2014, only two mAbs were registered; end of October 2023, more than ten mAbs are registered or have been granted emergency use authorization, and many more are in (pre)clinical phases. Especially the COVID-19 pandemic has generated this surge in licensed monoclonal antibodies, although multiple phase 1 studies were already underway in 2019 for other infectious diseases such as malaria and yellow fever. Monoclonal antibodies could function as prophylaxis (i.e., for the prevention of malaria), or could be used to treat (tropical) infections (i.e., rabies, dengue fever, yellow fever). This review focuses on the discussion of the prospects of, and obstacles for, using mAbs in the prevention and treatment of (tropical) infectious diseases seen in the returning traveler; and provides an update on the mAbs currently being developed for infectious diseases, which could potentially be of interest for travelers.https://doi.org/10.1186/s40794-023-00212-xMonoclonal antibodiesTropical infectious diseaseProphylaxisMalariaTravelers |
| spellingShingle | Hanna K. de Jong Martin P. Grobusch Monoclonal antibody applications in travel medicine Tropical Diseases, Travel Medicine and Vaccines Monoclonal antibodies Tropical infectious disease Prophylaxis Malaria Travelers |
| title | Monoclonal antibody applications in travel medicine |
| title_full | Monoclonal antibody applications in travel medicine |
| title_fullStr | Monoclonal antibody applications in travel medicine |
| title_full_unstemmed | Monoclonal antibody applications in travel medicine |
| title_short | Monoclonal antibody applications in travel medicine |
| title_sort | monoclonal antibody applications in travel medicine |
| topic | Monoclonal antibodies Tropical infectious disease Prophylaxis Malaria Travelers |
| url | https://doi.org/10.1186/s40794-023-00212-x |
| work_keys_str_mv | AT hannakdejong monoclonalantibodyapplicationsintravelmedicine AT martinpgrobusch monoclonalantibodyapplicationsintravelmedicine |